BACKGROUND. TGF-β has potent profibrotic activity in vitro and has long been implicated
in systemic sclerosis (SSc), as expression of TGF-β–regulated genes is increased in the skin …

Objective To assess the safety and effectiveness of imatinib mesylate in the treatment of
diffuse cutaneous systemic sclerosis (dcSSc). Methods In this phase IIa, open-label, single-arm …

Systemic sclerosis (SSc) is a multisystem life-threatening fibrosing disorder that lacks effective
treatment. The link between the inflammation observed in organs such as the skin and …

Objective T cells play a key role in the pathogenesis of early systemic sclerosis. This study
was undertaken to assess the safety and efficacy of abatacept in patients with diffuse …

Objective To assess cumulative survival rates and identify independent predictors of
mortality in patients with incident systemic sclerosis (SSc)–associated pulmonary arterial …

Objectives Determine global skin transcriptome patterns of early diffuse systemic sclerosis (SSc)
and how they differ from later disease. Methods Skin biopsy RNA from 48 patients in the …

Objective To assess the safety and efficacy of treatment with belimumab in patients with
early diffuse cutaneous systemic sclerosis (dc SS c) treated with background mycophenolate …

Objective To define a pharmacodynamic biomarker based on gene expression in skin that
would provide a biologic measure of the extent of disease in patients with diffuse cutaneous …

Introduction Tyrosine kinase inhibitors (TKI) are medications of interest in the treatment of
Systemic Sclerosis (SSc) because of their ability to inhibit pathways involved in fibrosis. In this …

Racial differences exist in the severity of systemic sclerosis (SSc). To enhance our knowledge
about SSc in African Americans, we established a comprehensive clinical database from …